Annual CFF
$10.66 M
+$4.64 M+76.92%
December 31, 2024
Summary
- As of February 22, 2025, SAGE annual cash flow from financing activities is $10.66 million, with the most recent change of +$4.64 million (+76.92%) on December 31, 2024.
- During the last 3 years, SAGE annual CFF has fallen by -$2.67 million (-20.03%).
- SAGE annual CFF is now -98.38% below its all-time high of $659.36 million, reached on December 31, 2018.
Performance
SAGE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$2000.00
-$1.04 M-100.19%
December 31, 2024
Summary
- As of February 22, 2025, SAGE quarterly cash flow from financing activities is -$2000.00, with the most recent change of -$1.04 million (-100.19%) on December 31, 2024.
- Over the past year, SAGE quarterly CFF has dropped by -$8.07 million (-100.02%).
- SAGE quarterly CFF is now -100.00% below its all-time high of $643.11 million, reached on March 31, 2018.
Performance
SAGE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$10.66 M
+$260.00 K+2.50%
December 31, 2024
Summary
- As of February 22, 2025, SAGE TTM cash flow from financing activities is $10.66 million, with the most recent change of +$260.00 thousand (+2.50%) on December 31, 2024.
- Over the past year, SAGE TTM CFF has dropped by -$1.47 million (-12.14%).
- SAGE TTM CFF is now -98.93% below its all-time high of $992.55 million, reached on September 30, 2018.
Performance
SAGE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SAGE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +76.9% | -100.0% | -12.1% |
| 3 y3 years | -20.0% | +98.8% | -20.0% |
| 5 y5 years | -98.3% | -100.1% | -98.3% |
SAGE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -20.0% | +247.3% | -100.0% | +99.2% | -20.0% | +271.4% |
| 5 y | 5-year | -98.3% | +247.3% | -100.0% | +99.2% | -98.3% | +271.4% |
| alltime | all time | -98.4% | +247.3% | -100.0% | +99.8% | -98.9% | +271.4% |
Sage Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $10.66 M(+76.9%) | -$2000.00(-100.2%) | $10.66 M(+2.5%) |
| Sep 2024 | - | $1.04 M(-87.2%) | $10.40 M(-14.3%) |
| Jun 2024 | - | $8.07 M(+418.4%) | $12.14 M(+147.1%) |
| Mar 2024 | - | $1.56 M(-694.3%) | $4.91 M(-18.5%) |
| Dec 2023 | $6.03 M(+96.3%) | -$262.00 K(-109.5%) | $6.03 M(-4.6%) |
| Sep 2023 | - | $2.77 M(+227.0%) | $6.32 M(+32.3%) |
| Jun 2023 | - | $847.00 K(-68.3%) | $4.78 M(+21.2%) |
| Mar 2023 | - | $2.67 M(+9113.8%) | $3.94 M(+28.4%) |
| Dec 2022 | $3.07 M(-77.0%) | $29.00 K(-97.6%) | $3.07 M(+6.9%) |
| Sep 2022 | - | $1.23 M(+9353.8%) | $2.87 M(-17.0%) |
| Jun 2022 | - | $13.00 K(-99.3%) | $3.46 M(-63.6%) |
| Mar 2022 | - | $1.80 M(-1158.2%) | $9.51 M(-28.7%) |
| Dec 2021 | $13.33 M(-96.9%) | -$170.00 K(-109.4%) | $13.33 M(-96.9%) |
| Sep 2021 | - | $1.82 M(-70.1%) | $433.18 M(-0.4%) |
| Jun 2021 | - | $6.07 M(+7.9%) | $434.90 M(+1.3%) |
| Mar 2021 | - | $5.62 M(-98.7%) | $429.23 M(+0.6%) |
| Dec 2020 | $426.76 M(-29.8%) | $419.67 M(>+9900.0%) | $426.76 M(+4510.2%) |
| Sep 2020 | - | $3.54 M(+818.4%) | $9.26 M(-52.8%) |
| Jun 2020 | - | $386.00 K(-87.8%) | $19.63 M(-43.2%) |
| Mar 2020 | - | $3.16 M(+45.9%) | $34.59 M(-94.3%) |
| Dec 2019 | $607.62 M(-7.8%) | $2.17 M(-84.4%) | $607.62 M(+0.1%) |
| Sep 2019 | - | $13.92 M(-9.3%) | $607.09 M(+1.0%) |
| Jun 2019 | - | $15.34 M(-97.3%) | $601.25 M(+1.5%) |
| Mar 2019 | - | $576.20 M(>+9900.0%) | $592.44 M(-10.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | $659.36 M(+92.9%) | $1.63 M(-79.8%) | $659.36 M(-33.6%) |
| Sep 2018 | - | $8.08 M(+23.5%) | $992.55 M(+0.4%) |
| Jun 2018 | - | $6.54 M(-99.0%) | $988.16 M(+0.4%) |
| Mar 2018 | - | $643.11 M(+92.1%) | $984.38 M(+188.0%) |
| Dec 2017 | $341.82 M(+3.3%) | $334.82 M(+8981.1%) | $341.82 M(+4353.1%) |
| Sep 2017 | - | $3.69 M(+33.7%) | $7.68 M(-96.0%) |
| Jun 2017 | - | $2.76 M(+398.7%) | $193.58 M(+1.4%) |
| Mar 2017 | - | $553.00 K(-18.4%) | $190.83 M(-42.3%) |
| Dec 2016 | $330.98 M(+154.9%) | $678.00 K(-99.6%) | $330.98 M(+0.2%) |
| Sep 2016 | - | $189.59 M(>+9900.0%) | $330.33 M(+134.5%) |
| Jun 2016 | - | $10.00 K(-100.0%) | $140.88 M(-47.9%) |
| Mar 2016 | - | $140.70 M(>+9900.0%) | $270.46 M(+108.3%) |
| Dec 2015 | $129.87 M(-11.6%) | $31.00 K(-77.4%) | $129.87 M(+0.2%) |
| Sep 2015 | - | $137.00 K(-99.9%) | $129.59 M(-42.3%) |
| Jun 2015 | - | $129.59 M(>+9900.0%) | $224.61 M(+138.9%) |
| Mar 2015 | - | $112.00 K(-145.0%) | $94.00 M(-36.0%) |
| Dec 2014 | $146.87 M(+544.6%) | -$249.00 K(-100.3%) | $146.87 M(-0.3%) |
| Sep 2014 | - | $95.16 M(-9402.4%) | $147.38 M(+111.4%) |
| Jun 2014 | - | -$1.02 M(-101.9%) | $69.71 M(-1.5%) |
| Mar 2014 | - | $52.98 M(>+9900.0%) | $70.76 M(+210.6%) |
| Dec 2013 | $22.78 M(+153.2%) | $261.00 K(-98.5%) | $22.78 M(+1.2%) |
| Sep 2013 | - | $17.49 M(>+9900.0%) | $22.52 M(+347.8%) |
| Jun 2013 | - | $30.00 K(-99.4%) | $5.03 M(+0.6%) |
| Mar 2013 | - | $5.00 M | $5.00 M |
| Dec 2012 | $9.00 M | - | - |
FAQ
- What is Sage Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Sage Therapeutics?
- What is Sage Therapeutics annual CFF year-on-year change?
- What is Sage Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Sage Therapeutics?
- What is Sage Therapeutics quarterly CFF year-on-year change?
- What is Sage Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Sage Therapeutics?
- What is Sage Therapeutics TTM CFF year-on-year change?
What is Sage Therapeutics annual cash flow from financing activities?
The current annual CFF of SAGE is $10.66 M
What is the all time high annual CFF for Sage Therapeutics?
Sage Therapeutics all-time high annual cash flow from financing activities is $659.36 M
What is Sage Therapeutics annual CFF year-on-year change?
Over the past year, SAGE annual cash flow from financing activities has changed by +$4.64 M (+76.92%)
What is Sage Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SAGE is -$2000.00
What is the all time high quarterly CFF for Sage Therapeutics?
Sage Therapeutics all-time high quarterly cash flow from financing activities is $643.11 M
What is Sage Therapeutics quarterly CFF year-on-year change?
Over the past year, SAGE quarterly cash flow from financing activities has changed by -$8.07 M (-100.02%)
What is Sage Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SAGE is $10.66 M
What is the all time high TTM CFF for Sage Therapeutics?
Sage Therapeutics all-time high TTM cash flow from financing activities is $992.55 M
What is Sage Therapeutics TTM CFF year-on-year change?
Over the past year, SAGE TTM cash flow from financing activities has changed by -$1.47 M (-12.14%)